SG11201811549UA - Boronic acid derivatives and therapeutic uses thereof - Google Patents
Boronic acid derivatives and therapeutic uses thereofInfo
- Publication number
- SG11201811549UA SG11201811549UA SG11201811549UA SG11201811549UA SG11201811549UA SG 11201811549U A SG11201811549U A SG 11201811549UA SG 11201811549U A SG11201811549U A SG 11201811549UA SG 11201811549U A SG11201811549U A SG 11201811549UA SG 11201811549U A SG11201811549U A SG 11201811549UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- science park
- san diego
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/05—Cyclic compounds having at least one ring containing boron but no carbon in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 011111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/005662 Al 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: Declarations under Rule 4.17: C07F 5/02 (2006.01) A61P 31/00 (2006.01) CO7F 5/04 (2006.01) A61P 31/04 (2006.01) — as to applicant's entitlement to apply for and be granted a A61K 31/69 (2006.01) patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the (21) International Application Number: earlier application (Rule 4.17(iii)) PCT/US2017/039787 Published: (22) International Filing Date: — with international search report (Art. 21(3)) 28 June 2017 (28.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/357,165 30 June 2016 (30.06.2016) US (71) Applicant: REMPEX PHARMACEUTICALS, INC. [US/US]; The Medicines Company, 3033 Science Park Rd., Suite 200, San Diego, CA 92121 (US). (72) Inventors: HECKER, Scott; 3033 Science Park Rd., Suite _ 200, San Diego, CA 92121 (US). REDDY, Raja K.; 3033 Science Park Rd., Suite 200, San Diego, CA 92121 (US). — GLINKA, Tomasz; 3033 Science Park Rd., Suite 200, San = Diego, CA 92121 (US). RODNY, Olga; 3033 Science Park Rd., Suite 200, San Diego, CA 92121 (US). = Agent: ALTMAN, Daniel E.; Knobbe, Martens, Olson & (74) = Bear, LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (81) = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, — MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = = Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, — GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — 1-1 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, k r ) N KM, ML, MR, NE, SN, TD, TG). 0 O_ 0 (54) Title: BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF 1-1 0 (57) : Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and ei preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, 13-lactamase C: inhibitors (BLIs).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662357165P | 2016-06-30 | 2016-06-30 | |
PCT/US2017/039787 WO2018005662A1 (en) | 2016-06-30 | 2017-06-28 | Boronic acid derivatives and therapeutic uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811549UA true SG11201811549UA (en) | 2019-01-30 |
Family
ID=60785544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811549UA SG11201811549UA (en) | 2016-06-30 | 2017-06-28 | Boronic acid derivatives and therapeutic uses thereof |
Country Status (23)
Country | Link |
---|---|
US (4) | US10294249B2 (en) |
EP (1) | EP3478693B1 (en) |
JP (1) | JP7060245B2 (en) |
KR (1) | KR102403296B1 (en) |
CN (1) | CN109415386B (en) |
AU (1) | AU2017290060B2 (en) |
BR (1) | BR112018077015B1 (en) |
CA (1) | CA3026582A1 (en) |
CL (1) | CL2018003681A1 (en) |
CO (1) | CO2018013978A2 (en) |
DK (1) | DK3478693T3 (en) |
ES (1) | ES2894251T3 (en) |
IL (1) | IL263450B (en) |
MX (1) | MX2018015892A (en) |
MY (1) | MY196909A (en) |
PH (1) | PH12018502747A1 (en) |
PL (1) | PL3478693T3 (en) |
PT (1) | PT3478693T (en) |
SA (1) | SA518400742B1 (en) |
SG (1) | SG11201811549UA (en) |
UA (1) | UA124464C2 (en) |
WO (1) | WO2018005662A1 (en) |
ZA (1) | ZA201808327B (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3412676T3 (en) | 2010-08-10 | 2021-04-06 | Melinta Therapeutics, Inc. | Cyclic boronic acid ester derivatives, method for the preparation and therapeutic uses thereof |
US9403850B2 (en) | 2013-01-10 | 2016-08-02 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
JP6622721B2 (en) | 2014-06-11 | 2019-12-18 | ベナトルクス ファーマシューティカルズ,インク. | Beta-lactamase inhibitor |
US10662205B2 (en) | 2014-11-18 | 2020-05-26 | Qpex Biopharma, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
EP3347008B1 (en) | 2015-09-11 | 2022-03-09 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
DK3478693T3 (en) | 2016-06-30 | 2021-09-20 | Qpex Biopharma Inc | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF |
JOP20190188A1 (en) | 2017-02-01 | 2019-08-01 | Rempex Pharmaceuticals Inc | Apparatus and continuous flow process for production of boronic acid derivative |
WO2018165048A1 (en) | 2017-03-06 | 2018-09-13 | VenatoRx Pharmaceuticals, Inc. | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
US11332485B2 (en) | 2017-05-26 | 2022-05-17 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
WO2018218154A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
JP7377545B2 (en) * | 2017-10-11 | 2023-11-10 | キューペックス バイオファーマ, インコーポレイテッド | Boronic acid derivatives and their synthesis |
US20210361682A1 (en) * | 2018-04-20 | 2021-11-25 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CA3121130A1 (en) * | 2018-11-29 | 2020-06-04 | VenatoRx Pharmaceuticals, Inc. | Combination compositions comprising a beta-lactamase inhibitor and uses thereof |
CN114340639A (en) | 2019-06-19 | 2022-04-12 | Qpex生物制药有限公司 | Boronic acid derivatives and their therapeutic use |
TW202123945A (en) * | 2019-09-13 | 2021-07-01 | 日商鹽野義製藥股份有限公司 | Pharmaceutical composition having antibacterial activity |
EP4049680A4 (en) * | 2019-10-25 | 2024-01-10 | Sumitomo Pharma Co Ltd | Novel substituted condensed ring compound |
CN116034109A (en) * | 2020-03-18 | 2023-04-28 | Qpex生物制药有限公司 | Boric acid derivatives and therapeutic uses thereof |
WO2021226114A1 (en) * | 2020-05-05 | 2021-11-11 | Qpex Biopharma, Inc. | Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof |
CN116615431A (en) * | 2020-08-20 | 2023-08-18 | 辉诺生物医药科技(杭州)有限公司 | Boric acid compound |
KR20230167077A (en) * | 2021-04-05 | 2023-12-07 | 큐펙스 바이오파마 인코포레이티드 | Ceftibuten administration regimen |
BR112023017203A2 (en) | 2021-04-13 | 2023-11-07 | Tuojie Biotech Shanghai Co Ltd | BORIC ACID DERIVATIVE THAT ACTS AS A BETA-LACTAMASE INHIBITOR |
CN113150022B (en) * | 2021-04-23 | 2022-12-06 | 四川大学 | 3-substituted five-membered cyclic borate derivative, and pharmaceutical composition and pharmaceutical application thereof |
WO2023066292A1 (en) * | 2021-10-19 | 2023-04-27 | 上海济煜医药科技有限公司 | Tricyclic boronic acid derivative, and preparation method therefor and application thereof |
WO2023155869A1 (en) * | 2022-02-18 | 2023-08-24 | 辉诺生物医药科技(杭州)有限公司 | Crystalline form of new boric acid-based compound and preparation method therefor |
CN114716465A (en) * | 2022-05-06 | 2022-07-08 | 上海中医药大学 | Preparation method and application of bicyclic borate compound |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3686398A (en) * | 1970-07-20 | 1972-08-22 | Chevron Res | 10,9-boroxarophenanthrene as fungicides |
US4194047A (en) | 1975-11-21 | 1980-03-18 | Merck & Co., Inc. | Substituted N-methylene derivatives of thienamycin |
US4260543A (en) | 1978-07-03 | 1981-04-07 | Merck & Co., Inc. | Crystalline N-formimidoyl thienamycin |
US4409214A (en) | 1979-11-19 | 1983-10-11 | Fujisawa Pharmaceutical, Co., Ltd. | 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof |
US4353807A (en) * | 1981-03-24 | 1982-10-12 | Mobil Oil Corporation | Lubricants and fuels containing boroxarophenanthrene compounds |
FR2573070B1 (en) | 1984-11-13 | 1987-01-30 | Rhone Poulenc Sante | PROCESS FOR THE PREPARATION OF CARBONYL COMPOUNDS |
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
CA1283404C (en) | 1986-07-01 | 1991-04-23 | Shigeru Sanai | Cephalosporin compounds, processes for their preparation and antibacterial agents |
ZA893284B (en) | 1988-05-04 | 1990-03-28 | Igen Inc | Peptide analogs and their use as haptens to elicit catalytic antibodies |
US5442100A (en) | 1992-08-14 | 1995-08-15 | The Procter & Gamble Company | β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids |
US5888998A (en) | 1997-04-24 | 1999-03-30 | Synphar Laboratories, Inc. | 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors |
US6184363B1 (en) | 1997-06-13 | 2001-02-06 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
US6075014A (en) | 1997-06-13 | 2000-06-13 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
AU3124300A (en) | 1998-12-16 | 2000-07-03 | Northwestern University | Inhibitors of beta-lactamases and uses therefor |
WO2000035905A1 (en) | 1998-12-16 | 2000-06-22 | Northwestern University | INHIBITORS OF β-LACTAMASES AND USES THEREFOR |
TR200200795T2 (en) | 1999-09-25 | 2002-07-22 | Smithkline Beecham P. L. C. | Piperazine derivatives as 5-HT1B antagonists |
EP1227722A1 (en) | 1999-10-28 | 2002-08-07 | Merck & Co., Inc. | Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections |
AU2001292732A1 (en) | 2000-09-12 | 2002-03-26 | Larry C. Blasczcak | Beta-lactam analogs and uses therefor |
PL218196B1 (en) | 2000-09-14 | 2014-10-31 | Basilea Pharmaceutica Ag | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents |
WO2002054931A2 (en) | 2001-01-10 | 2002-07-18 | Bristol Myers Squibb Company P | Alpha-aminoboronic acids prepared by novel synthetic methods |
DE10118698A1 (en) | 2001-04-17 | 2002-11-07 | Jerini Ag | Immobilization method and arrangement of connections produced therewith on a planar surface |
WO2003057144A2 (en) * | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
FR2835186B1 (en) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS |
JP2003229277A (en) | 2002-02-04 | 2003-08-15 | Matsushita Electric Ind Co Ltd | Material for light emitting element, light emitting element and light emitting device using the same |
AUPS065102A0 (en) | 2002-02-20 | 2002-03-14 | Unisearch Limited | Fluorous acetalation |
EP1550657A4 (en) | 2002-09-11 | 2009-12-30 | Kureha Corp | Amine compounds and use thereof |
EP2325225B2 (en) | 2002-10-30 | 2019-12-11 | Sumitomo Chemical Company, Limited | Complex aryl copolymer compounds and polymer light emitting devices made by using the same |
US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
WO2004058679A2 (en) | 2002-12-20 | 2004-07-15 | Migenix Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
JP4233365B2 (en) | 2003-03-25 | 2009-03-04 | 三井化学株式会社 | Azadiol complex compound and optical recording medium using the compound |
WO2005033090A1 (en) | 2003-10-06 | 2005-04-14 | Sumitomo Chemical Company, Limited | Aromatic compound |
EP1678180B1 (en) | 2003-10-10 | 2007-08-08 | Pfizer Products Incorporated | Substituted 2h-[1,2,4]triazolo 4,3-a pyrazines as gsk-3 inhibitors |
KR100918322B1 (en) * | 2003-11-12 | 2009-09-22 | 페노믹스 코포레이션 | Heterocyclic boronic acid compounds |
TW200600494A (en) | 2004-03-08 | 2006-01-01 | Chugai Pharmaceutical Co Ltd | Bisphenyl compounds useful as vitamin d3 receptor agonists |
US20060019116A1 (en) | 2004-07-22 | 2006-01-26 | Eastman Kodak Company | White electroluminescent device with anthracene derivative host |
TW200618820A (en) | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
US20060178357A1 (en) | 2005-02-10 | 2006-08-10 | Buynak John D | Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases |
SI2343304T1 (en) | 2005-02-16 | 2015-08-31 | Anacor Pharmaceuticals, Inc. | Biocidal boronophthalide compounds |
US7612203B2 (en) | 2005-02-22 | 2009-11-03 | Teva Pharmaceutical Industries Ltd. | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof |
WO2006101779A2 (en) | 2005-03-15 | 2006-09-28 | The University Of Chicago | Non-aqueous electrolytes for lithium ion batteries |
US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
RS52068B (en) | 2005-12-07 | 2012-06-30 | Basilea Pharmaceutica Ag. | Useful monobactam antibiotics |
CN101420854B (en) | 2006-02-16 | 2013-08-07 | 安纳考尔医药公司 | Boron-containing small molecules as anti-inflammatory agents |
JP2010504967A (en) | 2006-09-27 | 2010-02-18 | メルク エンド カムパニー インコーポレーテッド | Novel β-lactamase inhibitor |
JP2010521517A (en) | 2007-03-23 | 2010-06-24 | バジリア ファルマスーチカ アーゲー | Combination drugs for the treatment of bacterial infections |
CA2694068C (en) * | 2007-07-23 | 2016-08-30 | The Board Of Trustees Of The University Of Illinois | System for controlling the reactivity of boronic acids |
EA201070339A1 (en) * | 2007-09-06 | 2010-10-29 | Мерк Шарп Энд Домэ Корп. | ACTIVATORS OF SOLUBLE GUANYLATZYCLASES |
GB0719366D0 (en) | 2007-10-03 | 2007-11-14 | Smithkline Beecham Corp | Compounds |
US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
KR20100113485A (en) | 2007-11-13 | 2010-10-21 | 프로테즈 파마슈티칼스, 인크. | Beta-lactamase inhibitors |
MY162532A (en) | 2008-01-18 | 2017-06-15 | Merck Sharp & Dohme | Beta-lactamase inhibitors |
US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
WO2009140309A2 (en) | 2008-05-12 | 2009-11-19 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
CN102098918A (en) | 2008-05-13 | 2011-06-15 | 帕纳德制药公司 | Bioactive compounds for treatment of cancer and neurodegenerative diseases |
US20120046242A1 (en) | 2008-12-24 | 2012-02-23 | Massachusetts Institute Of Technology | Molecular activators of the wnt/beta-catenin pathway |
WO2010097675A1 (en) | 2009-02-27 | 2010-09-02 | Dhanuka Laboratories Ltd. | An improved preparation process for cefpodoxime proxetil |
EP2406233B1 (en) * | 2009-03-09 | 2013-11-13 | Bristol-Myers Squibb Company | Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists |
US20100292185A1 (en) | 2009-05-12 | 2010-11-18 | Burns Christopher J | Beta-lactamase inhibitors |
KR101460095B1 (en) | 2009-06-08 | 2014-11-10 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | Triazine derivatives and their therapeutical applications |
RU2012107163A (en) | 2009-07-28 | 2013-09-10 | Анакор Фармасьютикалз, Инк. | TRIZED SUBSTITUTE BORN-CONTAINING MOLECULES |
US20120329770A1 (en) | 2010-02-26 | 2012-12-27 | Gary Igor Dmitrienko | Cephalosporin derivatives useful as beta-lactamase inhibitors and compositions and methods of use thereof |
MA34169B1 (en) | 2010-03-31 | 2013-04-03 | Millennium Pharm Inc | 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID DERIVATIVES |
US20110288063A1 (en) | 2010-05-19 | 2011-11-24 | Naeja Pharmaceutical Inc. | Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors |
JP5603487B2 (en) | 2010-06-10 | 2014-10-08 | テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド | Process for the preparation of iodide |
PL3412676T3 (en) | 2010-08-10 | 2021-04-06 | Melinta Therapeutics, Inc. | Cyclic boronic acid ester derivatives, method for the preparation and therapeutic uses thereof |
PL2632927T3 (en) | 2010-10-26 | 2016-09-30 | Boronates as arginase inhibitors | |
AU2011329486A1 (en) | 2010-11-18 | 2013-04-18 | Glaxo Group Limited | Compounds |
EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
EP2508506A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Preparation of sitagliptin intermediates |
CN102320960A (en) | 2011-08-02 | 2012-01-18 | 安徽东健化工科技有限公司 | Preparation method of 6-fluoro salicylic acid |
WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
WO2013053372A1 (en) | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Boronic acid inhibitors of beta-lactamases |
WO2013056163A1 (en) | 2011-10-14 | 2013-04-18 | The Regents Of The University Of California | Beta-lactamase inhibitors |
CA2860142C (en) | 2011-12-22 | 2020-10-27 | Ares Trading S.A. | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
US20150018311A1 (en) | 2012-01-09 | 2015-01-15 | University of Tromsø | Therapeutic boron-containing compounds |
EP2615080A1 (en) | 2012-01-12 | 2013-07-17 | LEK Pharmaceuticals d.d. | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof |
US20150119363A1 (en) | 2012-02-15 | 2015-04-30 | Rempex Pharmaceuticals, Inc.. | Methods of treating bacterial infections |
US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
RU2654692C2 (en) * | 2012-12-07 | 2018-05-22 | Венаторкс Фармасьютикалс, Инк. | Beta-lactamase inhibitors |
US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
EA201591004A1 (en) | 2013-01-04 | 2016-02-29 | Ремпекс Фармасьютикалз, Инк. | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION |
AU2014204045B2 (en) | 2013-01-04 | 2018-10-18 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9403850B2 (en) | 2013-01-10 | 2016-08-02 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
WO2014151958A1 (en) | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
BR112015022994A2 (en) | 2013-03-15 | 2017-11-14 | Intrexon Corp | boron-containing diacylhydrazines |
LT3140310T (en) | 2014-05-05 | 2019-11-25 | Rempex Pharmaceuticals Inc | Synthesis of boronate salts and uses thereof |
US9687497B1 (en) | 2014-05-05 | 2017-06-27 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
MX2016015093A (en) | 2014-05-19 | 2017-03-27 | Rempex Pharmaceuticals Inc | Boronic acid derivatives and therapeutic uses thereof. |
US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
JP6622721B2 (en) | 2014-06-11 | 2019-12-18 | ベナトルクス ファーマシューティカルズ,インク. | Beta-lactamase inhibitor |
EP3164406A4 (en) | 2014-07-01 | 2018-04-04 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
WO2016065282A1 (en) | 2014-10-24 | 2016-04-28 | The Regents Of The University Of Michigan | Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels |
US10662205B2 (en) | 2014-11-18 | 2020-05-26 | Qpex Biopharma, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
JP6945452B2 (en) | 2015-04-24 | 2021-10-06 | レンペックス・ファーマシューティカルズ・インコーポレイテッド | How to treat bacterial infections |
DK3478693T3 (en) * | 2016-06-30 | 2021-09-20 | Qpex Biopharma Inc | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF |
JP7377545B2 (en) | 2017-10-11 | 2023-11-10 | キューペックス バイオファーマ, インコーポレイテッド | Boronic acid derivatives and their synthesis |
-
2017
- 2017-06-28 DK DK17821161.1T patent/DK3478693T3/en active
- 2017-06-28 BR BR112018077015-9A patent/BR112018077015B1/en active IP Right Grant
- 2017-06-28 PT PT17821161T patent/PT3478693T/en unknown
- 2017-06-28 ES ES17821161T patent/ES2894251T3/en active Active
- 2017-06-28 CN CN201780041247.XA patent/CN109415386B/en active Active
- 2017-06-28 US US15/636,424 patent/US10294249B2/en active Active
- 2017-06-28 JP JP2018565257A patent/JP7060245B2/en active Active
- 2017-06-28 WO PCT/US2017/039787 patent/WO2018005662A1/en unknown
- 2017-06-28 CA CA3026582A patent/CA3026582A1/en active Pending
- 2017-06-28 AU AU2017290060A patent/AU2017290060B2/en active Active
- 2017-06-28 EP EP17821161.1A patent/EP3478693B1/en active Active
- 2017-06-28 PL PL17821161T patent/PL3478693T3/en unknown
- 2017-06-28 MX MX2018015892A patent/MX2018015892A/en unknown
- 2017-06-28 UA UAA201812390A patent/UA124464C2/en unknown
- 2017-06-28 MY MYPI2018002676A patent/MY196909A/en unknown
- 2017-06-28 KR KR1020197003015A patent/KR102403296B1/en active IP Right Grant
- 2017-06-28 SG SG11201811549UA patent/SG11201811549UA/en unknown
-
2018
- 2018-12-03 IL IL263450A patent/IL263450B/en unknown
- 2018-12-10 ZA ZA2018/08327A patent/ZA201808327B/en unknown
- 2018-12-19 CL CL2018003681A patent/CL2018003681A1/en unknown
- 2018-12-21 CO CONC2018/0013978A patent/CO2018013978A2/en unknown
- 2018-12-21 PH PH12018502747A patent/PH12018502747A1/en unknown
- 2018-12-25 SA SA518400742A patent/SA518400742B1/en unknown
-
2019
- 2019-04-08 US US16/378,323 patent/US10570159B2/en active Active
-
2020
- 2020-02-18 US US16/793,965 patent/US11180512B2/en active Active
-
2021
- 2021-11-05 US US17/520,365 patent/US20220056055A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201806750WA (en) | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators | |
SG11201808231VA (en) | Delivery system | |
SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201408509PA (en) | Racecadotril lipid compositions |